IP Group's Microbiotica Raises £36M For Colitis Treatment
IP Group said Friday that its portfolio company Microbiotica Ltd. has raised £36 million ($48 million) to develop a treatment for ulcerative colitis, a chronic inflammatory bowel disease....To view the full article, register now.
Already a subscriber? Click here to view full article